SEC Info - AIkido Pharma Inc. - ‘8-K’ for 10/7/22

SEC Info℠

Home

Help

Please Sign In

AIkido Pharma Inc. – ‘8-K’ for 10/7/22

On: Friday, 10/7/22, at 5:00pm ET · For: 10/7/22 · Accession #: 1213900-22-62838 · File #: 0-05576

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/07/22  AIkido Pharma Inc.                8-K:8      10/07/22   10:184K                                   EdgarAgents LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 5: R1          Cover                                               HTML     47K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- ea166900-8k_aikidopharma_htm        XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- aiki-20221007_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- aiki-20221007_pre              XML     63K 
 2: EX-101.SCH  XBRL Schema -- aiki-20221007                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
10: ZIP         XBRL Zipped Folder -- 0001213900-22-062838-xbrl      Zip     15K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0000012239 i false 0000012239 2022-10-07 2022-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i October 7, 2022

i AIKIDO PHARMA INC.

(Exact name of registrant as specified in its charter)

i Delaware		i 000-05576		i 52-0849320
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i One Rockefeller Plaza, i 11th Floor, i New York, i NY		i 10020
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: i (703) i 993-9325

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, $0.0001 par value		i AIKI		The i Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On October 4, 2022, Dominari Financial Inc., a wholly owned subsidiary of AIkido Pharma Inc. (the “Company”), completed the purchase of 20% of the membership interests in Fieldpoint Private Securities, LLC, (the “Company”), a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”), otherwise pursuant to the terms of the Membership Interest Purchase Agreement, dated September 9, 2022 (“Purchase Agreement”). The second and final closing for the purchase of the balance of the membership interest in the Company will occur upon the final approval from FINRA. The complete terms of the Purchase Agreement can be found in Exhibit 2.1 of the Company’s September 9, 2022 Form 8-K, which is available online at www.sec.gov or on request from the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 7, 2022	AIKIDO PHARMA INC.

	By:	/s/ *Anthony Hayes*
	Name:	Anthony Hayes
	Title:	Chief Executive Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	10/7/22
	10/4/22
	9/9/22	8-K
		List all Filings

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/12/22  Dominari Holdings Inc.            8-K:1,8,9   9/09/22   12:443K                                   EdgarAgents LLC/FA

↑Top

Filing Submission 0001213900-22-062838 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)